Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | WRN | Q14191 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620757 | 0.90 | — | — | |
| SCHEMBL45106 | 0.90 | — | — | |
| SCHEMBL22635959 | 0.90 | — | — | |
| SCHEMBL2810989 | 0.89 | — | — | |
| SCHEMBL29406614 | 0.89 | — | — | |
| SCHEMBL18344257 | 0.88 | — | — | |
| SCHEMBL9914767 | 0.85 | ALDH1A1 (0.33) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL15940395 | 0.84 | — | — | |
| SCHEMBL706497 | 0.83 | — | — | |
| SCHEMBL16448969 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9517272-B2 | Temperature dependent activation of catalytic nucleic acids for controlled active substance release | MAGFORCE AG (DE) | 2016-12-13 | — | — | US | disclosed |
| US-20160129120-A1 | NANOCOMPLEXES OF MODIFIED PEPTIDES OR PROTEINS | TRUSTEES OF TUFTS COLLEGE | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129120-A1 | NANOCOMPLEXES OF MODIFIED PEPTIDES OR PROTEINS | LNPEP, ACP1, CRYAA | ALDH1A1 4413/4885CYP1A2 4533/4885HPGD 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.